Polyomavirus-specific T cells therapy (Kalaris Therapeutics)

N/A

Report date: 2025/04/23 20:01:04

Base Information

Drug NamePolyomavirus-specific T cells therapy (Kalaris Therapeutics)
Drug Alias NameBKV-specific T cell therapyBK Virus-specific T Lymphocytes
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsBK Polyomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViracyte Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKalaris Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsBK Polyomavirus Infections

Other Information

ATC CodeN/A
Related LinksN/A